
    
      This is a first-in-human, randomized, double-blind, placebo-controlled study consisting of 3
      parts. Part 1 will evaluate single ascending doses (SAD) of study drug. Part 2 will evaluate
      multiple ascending doses (MAD) of study drug administered for 7 days. Part 3 will evaluate
      MAD of study drug administered for 14 days.
    
  